Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lenbelintide · AZD6234

Other · developed by ASTRAZENECA

Phase 3 Most advanced trial
AZN Developer

What is Lenbelintide?

Lenbelintide (AZD6234) is an investigational agent given as a once-weekly subcutaneous injection. It is being studied in people with obesity or overweight.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD6234
Drug type
Other
Therapy area
Metabolic
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
5E55SLF9XR

Conditions studied

Obesity or Overweight

More from ASTRAZENECA

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Lenbelintide

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.